Mo et al., 2005 - Google Patents
Targeting Ubc9 for cancer therapyMo et al., 2005
- Document ID
- 17148320674025542222
- Author
- Mo Y
- Moschos S
- Publication year
- Publication venue
- Expert opinion on therapeutic targets
External Links
Snippet
Ubiquitin-conjugating enzyme (Ubc9) was originally thought to be a conjugating enzyme for ubiquitylation, but was later shown to be responsible for the most recently identified type of post-translational modification,(ie, SUMO [small ubiquitin-related modifier]) conjugation or …
- 101710033169 UBE2I 0 title abstract description 200
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mo et al. | Targeting Ubc9 for cancer therapy | |
Chan et al. | The Hippo pathway in biological control and cancer development | |
Pandey et al. | Amyloid precursor protein and amyloid precursor-like protein 2 in cancer | |
Visser et al. | LATS tumor suppressor: a new governor of cellular homeostasis | |
Irvine et al. | Rasputin, more promiscuous than ever: a review of G3BP | |
Kim et al. | Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability | |
Hall et al. | Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage | |
Xu et al. | Regulation of protein stability by GSK3 mediated phosphorylation | |
Li et al. | USP26 promotes esophageal squamous cell carcinoma metastasis through stabilizing Snail | |
US8211635B2 (en) | P53 modulator and cancer target | |
Yokoi et al. | Two mammalian homologs of yeast Rad23, HR23A and HR23B, as multifunctional proteins | |
AU8010800A (en) | Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors | |
CN108707668A (en) | A kind of long non-coding RNA SNHG15 and its application in preparing diagnosis and treatment cancer drug | |
Feng et al. | SUMO modification of menin | |
Wu et al. | Ubiquitin-like protein modifications in prostate and breast cancer | |
Date et al. | Borealin is repressed in response to p53/Rb signaling | |
US8759301B2 (en) | Gene fusion targeted therapy | |
Seghatoleslam et al. | Analysis of a novel human gene, LOC92912, over-expressed in hypopharyngeal tumours | |
Buddaseth et al. | Dysregulation of cell cycle control caused by overexpression of the oncogene pp32r1 (ANP32C) and the Tyr> His mutant pp32r1Y140H | |
EP2855532A1 (en) | Identification and functional expression of the mitochondrial pyruvate carrier, mpc1 | |
Joutsen | Regulation of cellular stress proteins in physiology and disease | |
Gérus et al. | Crosstalk between ribosome synthesis and cell cycle progression and its potential implications in human diseases | |
CN111363034B (en) | Antibody of NANOG Ser68, inhibitor and application | |
Qiao et al. | Unraveling the Oncogenic Characteristics of the Cytolinker, Plectin, in Esophageal Squamous Cell Carcinoma | |
Escuder-Rodríguez et al. | Beyond destruction: emerging roles of the E3 ubiquitin ligase Hakai |